background: The aim of this study was to evaluate the effect of trichostatin A (TSA) in a mouse model of endometriosis on serum tumour necrosis factor a (TNFa) levels, hotplate latency, lesion size and immunoreactivity to Trpv1, Pkc1 and Pgp9.5.
Introduction
Endometriosis, characterized by the ectopic presence of endometrial gland and stroma, is a common and debilitating gynecological disorder with an enigmatic pathogenesis (Giudice and Kao, 2004) . Even though the treatment of choice is surgery, medical treatment is often needed either as a first-line therapy or due to the high recurrence risk after surgery (Giudice and Kao, 2004) . The current medical treatment modalities for endometriosis are somewhat effective in relieving endometriosis-associated pain, yet this pain relief appears to be relatively short-term (Waller and Shaw, 1993) . In addition, they have many undesirable and sometimes severe, side effects (Kiilholma et al., 1995; Lessey, 2000; Bulun et al., 2005) . Consequently, more efficacious medical treatments, preferably with more tolerable sideeffects and better cost profiles, are sorely needed (Nothnick and D'Hooghe, 2003) . Unfortunately, among 15 registered and completed phase II/III clinical trials on endometriosis evaluating various compounds, a majority of them have so far not released their outcome in the public domain and the three that did so, reported results that are much less exciting than that seen in preclinical studies 2004; Olive et al., 2004) . Consequently, in treating women with endometriosis, the therapeutic efficacy is often measured by means of assessment of pain (Olive and Pritts, 2001 ). Yet pain, 'an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage' (Merskey and Bogduk, 1994) , or its relief, cannot be easily evaluated in in vitro studies. In most published animal studies that have evaluated the therapeutic potentials of promising compounds, the size, number, volume or weight of endometrial implants have been assessed but none, to our knowledge, have used a change in pain behaviors as an outcome measure.
Although the size, number, volume and weight of endometrial implants are all important outcome measures when evaluating a potential therapeutics, it should be noted that, from a patient's perspective, the relief of pain symptoms is of paramount importance, so as long as the lesions do not interfere with her daily life. Yet the exact relationships between the pain severity and various characteristics of disease, such as the stage, type, site or histology of endometriotic lesions, have not been well established and are often the subject of conflicting reports (Fedele et al., 1990 (Fedele et al., , 1992 Marana et al., 1991; Muzii et al., 1997; Vercellini, 1997; Whiteside and Falcone, 2003) . Perhaps more unsettling is a recent report from a phase II clinical trial on raloxifene in women with biopsy-proven endometriosis who received a second surgery; in these women the recurrent, biopsyproven endometriosis was not associated with the return of pain (Stratton et al., 2008) . This trial also found that raloxifene treatment was associated, unexpectedly, with an earlier return of pain symptoms as compared with placebo (Stratton et al., 2008) , despite previous promising preclinical in vitro and animal studies (Guo and Olive, 2007) .
In the last 3-4 years, evidence has been accumulating that endometriosis may be an epigenetic disease (Wu et al., 2005 (Wu et al., , 2007b Kim et al., 2007; Xue et al., 2007a,b; Izawa et al., 2008; Lee et al., 2009) , and, as such, may be treatable by pharmacological means. Indeed, in vitro studies have found that histone deacetylase inhibitors (HDACIs), such as trichostatin A (TSA), can suppress proliferation and cell cycle progression in endometrial stromal cells Guo, 2006, 2008a) , inhibit IL-1b-induced COX-2 expression , up-regulate PPARg (Wu and Guo, 2008b) , attenuate invasion and reactivate silenced E-cadherin gene expression (Wu et al., 2007a) . The treatment of adenomyosis, once called endometriosis interna, with valproic acid, another HDACI, has also been reported to be promising (Liu and Guo, 2008) . Despite these reports, so far there has been no published in vivo study evaluating the efficacy of HDACIs in treating endometriosis.
We hypothesized that TSA can suppress the growth of endometrial implants in vivo and, more importantly, reduce hyperalgesia in mice with induced endometriosis. Since TNFa and other proinflammatory cytokines have been reported to be associated with the severity of endometriosis (Richter et al., 2005) and also implicated in inflammatory hyperalgesia (Cunha et al., 1992) , we hypothesized that serum TNFa levels in mice with induced endometriosis would be elevated but that TSA treatment might reduce it. In addition, as both TRPV1 and PKC1 have been reported to be nociceptive mediators and PGP9.5 has been reported to be involved in the innervation of ectopic endometrium (Berkley et al., 2004; Tokushige et al., 2006a) , we hypothesized that their expression would be increased in endometrial implants as well as in endometrium and vagina because of visceral-viscero sensitization Christianson et al., 2007; Li et al., 2008) . We therefore sought to determine whether the TSA treatment would suppress the growth of endometrial implants, improve tolerance to noxious thermal stimulus, decrease serum TNFa levels and inhibit expression of Trpv1, Pkc1 and Pgp9.5 (a pan-neuronal marker) in mice with induced endometriosis.
Materials and Methods

Animals
A group of 30 adult female C57BL/6 mice (SCXK-2008-0002) , of 8 -9 weeks old and about 18 -20 g in weight, were purchased from the Laboratory Animal Science of Shanghai Medical College, Fudan University (Shanghai, China) and used for this study. They were maintained under controlled conditions with a light/dark cycle of 12/12 h and had access to food and water ad libitum.
All experiments were performed under the guidelines of the National Research Council's 'Guide for the Care and Use of Laboratory Animals' (Council, 1996) and approved by the institutional experimental animals review board of Shanghai OB/GYN Hospital, Fudan University.
Experiment protocol
After 3 days of acclimatization and before surgery, a baseline hotplate test (described below) was administrated to all mice and 200 -300 ml of peripheral blood was drawn, from the inner canthus vein of the right eye, for baseline measurement of serum TNFa levels. Then the mice were randomly divided into two groups, the SHAM group (n ¼ 10) and the ENDO group (n ¼ 20). Mice in the SHAM group received a sham endometriosis-inducing surgery, although the ENDO group (n ¼ 20) received a real endometriosis-inducing surgery (see Surgical Procedures section).
Two weeks after the surgery, the second hot plate test was administrated and peripheral blood was drawn. Then the ENDO group was further divided into two groups at random: Group T (for trichostatin A or TSA treatment, n ¼ 10) that received subcutaneous injections of TSA 0.5 mg/kg body weight in 40 ml of dimethyl sulfoxide (DMSO) daily for 4 weeks, and Group U (control, or untreated group, n ¼ 10) that received daily subcutaneous injections of 40 ml of DMSO alone. The SHAM group, or Group S, received the same treatment as Group U.
Four weeks after the treatment started, the final hotplate test was administrated and a similar amount of peripheral blood was drawn in all mice before sacrifice through cervical dislocation. The abdominal cavity was immediately reopened through the original incision, and the lesions were measured by two perpendicular diameters (D 1 and D 2 ) with a caliper, and the cross-sectional lesion area was calculated using the formula (D 1 Â D 2 Â p/4) as previously reported (Becker et al., 2005) . The number and total size (in mm 2 ) of ectopic lesions in Groups T and U were evaluated. Ectopic lesion tissues in Groups T and U or peritoneum tissues in Group S and uterine and (upper 1/2 part) vaginal tissues in all three groups were harvested and fixed immediately after collection in 10% formalin -acetic acid and embedded in paraffin for histopathologic examination and immunohistochemical analysis.
We note that the efficacy of TSA treatment can be evaluated based on ENDO mice, later subdivided into two groups, with one receiving TSA (Group T) and the other (Group U), the solvent of TSA. The main purposes of setting up the SHAM group were: (i) to see whether the hotplate test can be used to detect endometriosis-induced hyperalgesia or hypersensitivity in lieu of a more sophisticated apparatus that measures the mouse' sensitivity to increased vaginal distention (Berkley et al., 2001) ; and (ii) to see whether we could replicate the finding of central sensitization induced by endometriosis in mice (Berkley et al., 2001) ; and (iii) to see whether surgery alone would result in any changes in serum TNFa levels or pain behavior as measured by the hotplate test. It should be noted that this group was not used for the purpose of evaluating the therapeutic efficacy of TSA. It also should be noted that the use of TSA was because TSA is a benchmark HDACI, frequently used in in vitro studies and proved to have low toxicity in vivo (Nervi et al., 2001 ).
Surgical procedures
Surgery was performed under aseptic precautions to auto-transplant small pieces of uterus (the ENDO group) or fat (the SHAM group) to peritoneum in lower parts of the abdomen and pelvic cavity, similar to that described in published studies (Cummings and Metcalf, 1995; Cason et al., 2003; Berkley et al., 2004) . Prior to any invasive procedure, the mice were anaesthetized with 100 mg/kg ketamine hydrochloride. For the ENDO group, laparotomy was performed and the left uterine horns were removed. The excised horns, with connecting fat tissues removed as much as possible, were immersed in a sterile lactate solution and opened longitudinally. Each uterine segment was cut into four smaller fragments of roughly equal size. For mice in the SHAM group, laparotomy was performed and four pieces of fat tissues, roughly equal in size to the endometrial fragments used in the ENDO group, were separated and removed from the left uterine horn. A total of four uterine (ENDO) or fat fragments (SHAM) were sutured to the peritoneal wall of the lower part of the lateral abdominal and pelvic cavity with a 6/0 braided silk suture. Then the midline incision was closed with a 3/0 braided silk suture. After surgery, all mice were fed with 2 mg/l 17b-estradiol (Sigma, St. Louis, MO, USA) solution daily for 2 weeks. Penicillin of 40 000 U/d was administrated i.m. to all mice for 5 days to prevent infection after surgery.
Hotplate procedures
The hotplate test (Bannon and Malmberg, 2007) , or the test of sensitivity to the thermal nociception, was evaluated with a commercially available Hot Plate Analgesia Meter (Model BME-480, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences, Tianjin, China) consisting of a metal plate of 25 cm Â 25 cm in size, which can be heated to a constant temperature of 54.0 + 0.18C, on which a plastic cylinder (20 cm in diameter, 18 cm in height) was placed. Mice were brought to the testing room and allowed to acclimatize for 10 min before the test began.
The latency to respond to thermal stimulus, defined to be the time (in second) elapsed from the moment when the mouse was inserted inside the cylinder to the time when it licked or flicked its hind paws, or jolted or jumped off the hot plate. Each animal was tested only once in one session. The latency was calculated as the mean of two readings recorded at intervals of 24 h.
Measurement of serum levels of TNFa by ELISA
Serum levels of TNF-a were quantified by using a mouse specific enzymelinked immunosorbent assay (ELISA) kit following the manufacturer's instructions (R&D Systems Inc., Minneapolis, MN, USA). The minimum detectable level was 7.0 pg/ml for TNF-a. The intra-assay and inter-assay coefficients of variation were ,10% in this assay.
Immunohistochemistry
Serial 4-mm sections were obtained from each paraffin-embedded tissue block, with the first resultant slide being stained for H&E to confirm pathologic diagnosis, and the subsequent slides stained for Trpv1, Pkc1 and Pgp9.5. Routine deparaffinization and rehydration procedures were performed following published protocols (Sompuram et al., 2002) .
The rabbit polyclonal antibodies against Trpv1'Pkc1' and Pgp9.5 (ab63083, ab15505 and ab36171, respectively, all purchased from Abcam, Cambridge, UK) diluted to 1:200, 1:100 and 1:50, respectively, were used as primary antibodies. For antigen retrieval, the slides were heated at 988C in an EDTA buffer (pH 9.0) for a total of 30 min and cooled naturally at room temperature. Sections were then incubated overnight with the primary antibody at 48C. After slides were rinsed, the biotinylated secondary antibody, Supervision TM Universal (anti-rabbit) Detection Reagent (HRP) (GK500705, Shanghai Gene Tech Company, Shanghai, China), was incubated at room temperature for 30 min. The bound antibody complexes were stained for 3-5 min or until appropriate for microscopic examination with diaminobenzidine and then counterstained with hematoxylin and mounted.
Immunoreactivity staining was characterized quantitatively by digital image analysis using the Image Pro-Plus 6.0 (Media Cybernetics, Inc., USA) as reported in (Wang-Tilz et al., 2006) without prior knowledge of any of the clinicopathological information. Briefly, images were obtained with the microscope (Olympus BX51, Olympus, Tokyo, Japan) fitted with a digital camera (Olympus DP70, Olympus, Tokyo, Japan). A series of 10 random images on several sections were taken for each immunostained parameter to obtain a mean value. Staining was defined via color intensity, and a color mask was made. The mask was then applied equally to all images, and measurement readings were obtained. Immunohistochemical parameters assessed in the area detected included: (i) integrated optical density (IOD), (ii) total stained area (S) and (iii) mean optical density (MOD) which is defined as MOD ¼ IOD/S, equivalent to the intensity of stain in all positive cells.
For Trpv1, Pkc1 and Pgp9.5, the staining was predominantly localized to epithelial cells in eutopic and ectopic endometrium, vagina and in SHAM mice, peritoneum, hence only immunostaining in epithelial cells was evaluated. All sections were inspected independently by two persons (J.C.N. and Y.L.). Discrepancies, if occurred, were resolved by consensus.
Statistical analysis
The comparison of distributions of continuous variables between or among two or more groups was made using the t-test and ANOVA, respectively, and the paired t-test was used when the before-after comparison was made for the same group of subjects. Pearson's or Spearman's rank correlation coefficient was used when evaluating correlations between two variables when both variables are continuous or when at least one variable is ordinal. To see whether TSA treatment or Trpv1/ Pkc1/Pgp9.5 immunoreactivity or other possible factors were responsible for the change in hotplate latency or in serum TNFa levels before and after the treatment, a multiple linear regression model was used.
P-values of less than 0.05 were considered statistically significant. All computations were made with R 2.9.0 (Inhaka and Gentleman, 1996;  www.r-project.org).
Results
Two mice in Group U and another two in Group S died from unknown causes after surgery but before the treatment. Hence Groups T, U and S had 10, 8 and 8 mice, respectively. For the rest of ENDO (Groups T and U) mice, endometriosis was successfully induced (Fig. 1A, B and D) . Except for two mice in Group T, all ENDO mice exhibited fully formed cysts of .2 mm in diameter at !1 of the four transplanted sites. As expected, no cyst was found in any mice in Group S. However, adhesion was seen in 50% mice in Group S as a result of the sham surgery (Fig. 1C) . The proportion of mice with adhesions in the ENDO mice was in the range of 40%, similar to that in the SHAM mice.
Effect of TSA treatment on ectopic endometrium
TSA appeared to be well-tolerated in treated mice, consistent with the previous report (Nervi et al., 2001) . In mice (ENDO) with induced endometriosis, the number of lesions and size were positively correlated (Spearman's correlation coefficient r ¼ 0.72, P ¼ 0.0007). Mice treated with TSA (Group T) had an average of 2.1 [standard deviation (SD) ¼ 1.3], as compared with 2.6 (SD ¼ 1.1) lesions in the untreated mice (Group U). Similarly, mice in Group T had mean total lesion areas of 14.3 mm 2 (SD ¼ 13.3), as compared with 22.3 mm 2 (SD ¼ 9.6) in Group U. The average size of each lesion in TSA treated mice was significantly smaller than that in untreated mice [5.0 (4.2) versus 9.2 (3.3), or a reduction of 54.3%; P ¼ 0.03, t-test], suggesting that the TSA treatment had a suppressive effect on the lesion size.
Effect of surgery and TSA treatment on hotplate latency
We assessed hotplate responses at 548C prior to the surgical induction of endometriosis or sham surgery (Test 1), 2 weeks after the surgery (Test 2) and 4 weeks after the TSA or DMSO treatment (Test 3). As expected, there were no differences in Test 1 latency among the three groups (P ¼ 0.50, ANOVA). Yet 2 weeks after the surgery, but prior to the administration of TSA to the treatment group, the Test 2 latency in all three groups was significantly decreased as compared with that of Test 1 (Fig. 2 , P ¼ 0.003, paired t-test) and there was no difference in Test 2 latency between mice that received real (endometriosis-inducing) and sham surgery (P ¼ 0.59, t-test). This suggests that both induced endometriosis and the sham surgery significantly lowered the tolerance to noxious thermal stimulus as compared with the baseline, even though the location that received the stimulus is remote to the sites where endometrial or fat tissues were transplanted. SHAM mice also had reduced tolerance to noxious thermal stimulus possibly because of surgical trauma and adhesion. Unexpectedly, Test 2 latency in Group T was significantly shorter than that in Group U (Fig. 2, P ¼ 0.018, t-test) . Since the test was performed prior to the TSA treatment and the grouping of the two was made randomly, this difference was very likely a chance event in view of the rather moderate sample sizes in each group and of the standardized test procedure. Therefore, we used the change in latency (i.e. Test 3 latency -Test 2 latency) as an outcome measure to evaluate the TSA effect on latency. We found that mice that received TSA treatment for 4 weeks had a significant improvement in latency as compared with the untreated mice [2.38 (1.20) versus 20.60 (1.62), P ¼ 0.0008, unpaired t-test; Fig. 2 ]. The paired t-test also supported this finding: among the three groups of mice, only the treatment group (Group T) had a significant increase in Test 3 latency as compared with Test 2 (P ¼ 0.00006). For mice in Group T, there was no significant difference between Test 3 and Test 1 tolerance (P ¼ 0.23). This indicates that TSA treatment, but not DMSO treatment, successfully restored the normal tolerance to the noxious thermal stimulus that was impaired by induced endometriosis. Interestingly, Test 3 latency was negatively correlated with the number of lesions in mice with induced endometriosis (Spearman's rank correlation r ¼ 20.48, P ¼ 0.042). It was also negatively associated with the total areas of all lesions, but the correlation coefficient did not reach statistical significance (r ¼ 20.40, P ¼ 0.098). This seems to suggest that the severity of endometriosis, as measured by the number of lesions, correlates with sensitivity to of noxious thermal stimulus.
Effect of surgery and TSA treatment on serum levels of TNFa
We also evaluated the dynamic change in serum TNFa levels at approximately the same time as the hotplate tests (Fig. 3) . As expected, there were no differences in serum TNFa levels before the surgery in any groups (P ¼ 0.97, Kruskal's test, Fig. 3 ). Two weeks after the surgery, but before the treatment intervention, the serum TNFa levels in the TSA treated (Group T) and untreated (Group U) mice were also comparable [0.10 (0.04) versus 0.08 (0.03) pg/ml, P ¼ 0.24, t-test], also as expected. In contrast, the levels in mice which received the sham surgery (Group S) seemed to be lower than that in mice in either Group T or U. In fact, the serum TNFa levels in Group S mice were 33% lower than in mice that received the real surgery [0.06 (0.04) versus 0.09 (0.04) pg/ml], and the difference was statistically significant (P ¼ 0.022). This seems to suggest that induced endometriosis resulted in more peripheral production of TNFa than did the sham surgery. At the end of study, the serum TNFa level in the mice that received the sham surgery was significantly lower than that in Group U (Fig. 3 , P ¼ 0.021). This suggests that mice received the sham surgery had consistently lower serum TNFa levels than did mice with induced endometriosis, even though no difference in Test 2 or Test 3 latency was found between them.
Although all three groups had significantly reduced serum TNFa levels by the end of the experiment as compared with that measured 2 weeks after the surgery (P ¼ 0.0004, P ¼ 0.0005 and P ¼ 0.0005, for Groups T, U and S, respectively, all by paired t-test), the reduction in Group T was the most prominent [the mean reduction was 0.083 (0.048), 0.047 (0.033) and 0.047 (0.041) pg/ml, respectively, or 82.6, 59.4 and 78.8% reduction for Groups T, U and S, respectively]. The reduction in the treatment group was only marginally significant as compared with the untreated group (P ¼ 0.076, t-test). These results, taken together, seem to suggest that even in the absence of any intervention, the serum TNFa levels decrease as induced endometriosis progresses (in the untreated group) or the initial surgical trauma subsides (as in SHAM group). TSA treatment appeared to facilitate the decrease, but only marginally as compared with DMSOtreated (i.e. Group U) mice with induced endometriosis.
The effect of TSA treatment on the changes in both serum TNFa levels and hotplate latency can be best illustrated by Fig. 4 , which shows that all mice that received TSA treatment fell into the lower right quadrant, indicating improvement, as a result of the treatment, in both the hotplate latency and the serum TNFa level. In contrast, only two out eight mice that did not receive the treatment were in the same quadrant, and the other six fell into the lower or upper left quadrant, with deteriorated hotplate latency (Fig. 4) . Interestingly, the Test 3 latency was negatively correlated with the serum TNFa level measured roughly at the same time in mice with induced endometriosis (r ¼ 20.68, P ¼ 0.0028). However, when data from Group S were also included, the correlation vanished (r ¼ 20.04, P ¼ 0.85), suggesting that serum TNFa levels do not relate to the degree of hyperalgesia resulting from endometriosis.
Effect of surgery and TSA treatment on Trpv1, Pkc1 and Pgp9.5 immunochemistry Figure 5 shows the Trpv1, Pkc1 or Pgp9.5 immunostaining in eutopic or ectopic endometrium or vagina in mice in Groups T, U and S. It can be seen that the staining of Trpv1, Pkc1 and Pgp9.5 was seen mostly in cytoplasm and was predominantly localized in epithelial cells of eutopic endometrium and vagina and ectopic endometrium.
We found that there was a significant difference in immunoreactivity to Trpv1 in eutopic endometrium (P ¼ 0.02, Kruskal's test), to Pkc1 in ectopic endometrium (P ¼ 0.009) and to Pgp9.5 in vagina (P ¼ 0.02) among the three groups, respectively (Fig. 6) . In particular, the differences between Groups T and U were all highly significant (P ¼ 0.004, 0.001 and 0.006, respectively), although no significant difference was found between Groups U and S (all P-values . 0.05). Thus, mice treated with TSA had significantly lower immunostaining to Trpv1 in eutopic endometrium, to Pkc1 in ectopic endometrium and to Pgp9.5 in vagina, respectively, as compared with the untreated mice. Although in other organs (e.g. Trpv1 in vagina and ectopic endometrium) the trend was similar, the differences did not reach statistical significance. These results suggest that, as compared with the untreated mice, the TSA treatment resulted in significant decreases in immunostaining to all three pain mediators in some specific organs, but not in other organs evaluated.
Even though Trpv1, Pkc1 and Pgp9.5 immunoreactivity levels in tissues other than those depicted in Fig. 6 were also higher in untreated mice as compared with SHAM mice, the differences did not reach statistical significance (P . 0.05).
Trpv1, Pkc1 and Pgp9.5 immunochemistry and their relationship with pain behavior and serum levels of TNFa Given the significant changes in pain behavior, the immunoreactivity to three pain mediators and suggestive evidence for the reduction of serum levels of TNFa which is a proinflammatory cytokine and also a pain mediator (Sommer and Kress, 2004) , in mice treated with TSA, we wondered whether there existed any relationship between the hotplate latency, serum TNFa level and immunoreactivity to the three pain mediators.
We found that, in ectopic endometrium, the Trpv1 immunostaining levels were correlated negatively with the hotplate latency (r ¼ 20.86, P ¼ 4.6 Â 10 26 ) and positively with the serum TNFa levels (r ¼ 0.59, P ¼ 0.009). In mice with induced endometriosis, the serum TNFa levels were positively correlated with both Pkc1 (r ¼ 0.59, P ¼ 0.009) and Pgp9.5 immunoreactivity levels (r ¼ 0.49, P ¼ 0.039) in the eutopic endometrium. In SHAM mice, the serum TNFa levels were positively correlated with Pgp9.5 immunoreactivity levels (r ¼ 0.90, P ¼ 0.003) in vagina.
Determinants of changes in hotplate latency
We carried out a multiple linear regression analysis of the determinants of changes in hotplate latency in mice with induced endometriosis. For the change in hotplate latency from before to after treatment, we found that TSA treatment, Trpv1 immunoreactivity levels in the ectopic endometrium and the average lesion size were all associated with the change (Table I ). This suggests that TSA treatment, Trpv1 expression in ectopic endometrium and the average lesion size may have been jointly responsible for the change in the response latency.
Discussion
Endometriosis induces centrally mediated hypersensitivity
Persistent, episodic or chronic visceral pains such as chronic pelvic pain are more prevalent in women than in men (Berkley, 1997; Fillingim and Gear, 2004) , and some forms of pain, like dysmenorrhea, occurs exclusively in women. Visceral pain, of various kinds, is the most common complaint that prompts women who are later diagnosed or have already been diagnosed with endometriosis to seek medical attention, and is also a critical outcome measure when evaluating therapeutic efficacy (Guo, 2008 ). Yet the evaluation of pain behavior changes in animal studies of endometriosis has received scant attention. Berkley and associates were the first to introduce the behavior evaluation in animal models of endometriosis (Berkley et al., 2001 (Berkley et al., , 2004 Berkley, 2005) . Their meticulous studies have shown convincingly that induced endometriosis also yields vaginal hyperalgesia as manifested by heightened sensitivity to vaginal distention, and this effect is likely to be centrally mediated (Berkley et al., 2007) , which appears to be corroborated by human studies (Bajaj et al., 2003) . The visceral-viscero cross-sensitization also has been independently demonstrated in other studies (Appleyard et al., 2007) . In all published preclinical studies that evaluate potentially therapeutic compounds, however, pain behavioral changes have not been evaluated in animal models of endometriosis. The lack of pain behavior evaluation could have contributed to the failure of some phase II/III clinical trials on endometriosis despite promising preclinical findings (Guo and Olive, 2007) . The likely central sensitization resulting from induced endometriosis conceivably should uniformly enhance overall responses to noxious stimulation or increase sensitivity to overall nociceptive stimulation. Although hotplate test measures response latency to high intensity stimulus and is thus an 'acute pain test' (Bannon and Malmberg, 2007) , the response nonetheless is mediated by spinal-brain stem-spinal reflexes (Vierck, 2006) . Indeed, our data suggest that mice with induced endometriosis have reduced response latency and the response continues to deteriorate if endometriosis is left untreated. These observations support the notion that endometriosis results in increased centrally mediated sensitization to noxious stimuli (Berkley et al., 2007) . Although the exact mechanisms are still unclear, it is possible that endometriosis-induced inflammation causes persistent peripheral and visceral pain, possibly through the involvement of peripheral and central neuroplastic changes. Persistent, low-grade chronic inflammation may also sensitize visceral afferent pathways, and possibly sensitize non-neuronal resident cells of the eutopic endometrium through the activation of Trpv1, manifested as increased Trpv1 immunoreactivity in the uterus as seen in our study. Regardless, our results and the findings from Berkley's group strongly argue for the inclusion of pain behavior measurement such as a hotplate test as an outcome measure for animal studies of endometriosis, especially when evaluating the therapeutic potentials of a compound.
In addition, the induced endometriosis also causes elevated serum levels of TNFa in the early stage of induced endometriosis, possibly as a result of inflammation. Interestingly, the serum levels somehow decrease as the disease apparently progresses. This may explain the recent finding that serum TNFa levels seem to have little value in non-invasive diagnosis of endometriosis (Kalu et al., 2007; Othman Eel et al., 2008; Seeber et al., 2008) , seemingly contrasting earlier reports (Bedaiwy et al., 2002) . Alternatively, the administration of DMSO may somehow have reduced serum levels of TNFa because of the reported anti-inflammatory effect of DMSO, which has been used to treat intractable interstitial cystitis, radiation cystitis, chronic prostatitis and chronic female trigonitis (Shirley et al., 1978) . DMSO is now used most widely as a topical analgesic (Swanson, 1985) . We realized this fact belatedly only after the experiment was ended. Future experiments without the use of DMSO in control animals should shed more light on this issue.
Therapeutic potentials of HDACIs
Even though the possible therapeutic effect of DMSO cannot be ruled out completely, it is remarkable that mice that received the TSA treatment appear to have significantly reduced average lesion sizes as compared with DMSO-treated mice, consistent with the in vitro results reported previously Guo, 2006, 2008a) . More remarkably, TSA treatment also resulted in significantly improved response to noxious thermal stimulus as compared with untreated mice, possibly due to the suppression of expression of COX-2 and other pain mediators.
In conjunction with the improvement in thermal response latency, TSA treatment, as compared with controls, significantly reduced TSA reduces endometriosis growth and hyperalgesia Trpv1 expression in eutopic endometrium, Pkc1 expression in ectopic endometrium and Pgp9.5 expression in vagina. As Trpv1 and Pkc1 are important players in pain perception (see below), the positive effect of TSA on these pain mediators, along with desired changes in pain behavior and average lesion size, strongly suggests that HDACIs are promising candidates for treating endometriosis.
Trpv1 and endometriosis-related pain
TRPV1 is mainly expressed in primary neurons, but in the last 5 years it has now been found also in the human bronchial epithelial cells (Veronesi et al., 1999), brain (Mezey et al., 2000) , kidney (Tsutsumi et al., 2001) and in keratinocytes in the epidermis (Denda et al., 2001; Stander et al., 2004) . Although the exact biological significance of TRPV1 overexpression in endometriosis remains to be elucidated, it is possible that TRPV1-expressing epithelial and stromal cells may have a sensory role, working in concert with afferent nerves and leading to adenomyosis-associated dysmenorrhea, as in urinary bladder epithelial and interstitial cells (Birder et al., 2001; HannaMitchell and Birder, 2008) . Consistent with this notion, our preliminary work shows that primary adenomyotic stromal cells do express TRPV1 (Li et al., unpublished observation) and the expression can be reduced by the treatment of TSA, which is consistent with the clinical finding that valproic acid (an HDACI as TSA) treatment relieves dysmenorrhea in adenomyosis (Liu and Guo, 2008) . In addition, exogenously applied capsaicin increased intracellular Ca 2þ in primary stromal cells derived from endometriotic tissues, but the TRPV1 antagonist, capsazepine, blocked the effects of capsaicin (Liu et al., unpublished observation) , identical to that reported in rat urothelial cultures (Birder et al., 2001) . Alternatively, TRPV1 overexpression may induce release of proinflammatory mediators such as COX-2 as reported in human keratinocytes (Southall et al., 2003) . Further investigation on the precise biological significance of TRPV1 overexpression in endometriosis-related pain is warranted.
PKC1 and endometriosis-related pain
PKC1 has been identified to be an important intracellular mediator involved in mechanical hyperalgesia (Khasar et al., 1999) , inflammation-induced nociceptor sensitization (Khasar et al., 1999; Numazaki et al., 2002; Sweitzer et al., 2004) and the transition from acute to chronic inflammatory pain (Aley et al., 2000; Parada et al., 2003 Parada et al., , 2005 . Even more important and relevant is the report that it is involved in estrogen-mediated mechanical hyperalgesia and inflammatory pain (Dina et al., 2001; Hucho et al., 2006) . PKC1 also modulates TRPV1 activation (Premkumar and Ahern, 2000; Nilius et al., 2007) . Our finding, that TSA treatment resulted in significantly reduced PKC1 expression in ectopic endometrium, concomitant with the reduction in Trpv1 expression and the improvement in hotplate latency appears to suggest that PKC1 is likely to be involved in endometriosis-induced pain and may be a marker for therapeutic efficacy. It is unclear as why to PKC1 immunostaining did not correlate well with Trpv1 in ectopic endometrium.
PGP9.5 and endometriosis-related pain
PGP9.5 is a pan neuronal marker and has been shown to be expressed in neurites accompanying blood vessels and extending into nearby luminal epithelial layers in ectopic endometrium (Berkley et al., 2004) . Recently, it has been shown that nerve fibers in the eutopic and ectopic endometrium are stained positive with PGP9.5 (Tokushige et al., 2006a (Tokushige et al., ,b, 2007 Al-Jefout et al., 2007) . In our study, Pgp9.5 immunostaining was predominantly localized to epithelial cells in eutopic and ectopic endometrium, vagina and in SHAM mice, peritoneum. Although we did not use other markers for nerve fibers, we note that PGP9.5 expression in non-neuronal cells has been reported (Yamazaki et al., 2002) . The reduction of Pgp9.5 expression in vagina as a result of TSA treatment may be in line with the report that medical treatment reduces nerve fiber density and nerve growth factor (NGF) and NGF receptor, p75, expression in peritoneal endometriotic lesions (Tokushige et al., 2008a,b) . Future studies using NGF or other markers should provide more insight into this matter.
Inflammation and pain in endometriosis
Endometriosis is characterized by inflammation and increased production of proinflammatory cytokines and chemokines, including MIP-1a (Lin et al., 2006) . It has been reported that MIP-1a sensitizes Trpv1 through PKC-mediated signaling (Zhang et al., 2005) . Although we did find differences in Trpv1 in eutopic endometrium, in Pkc1 in ectopic endometrium and in Pgp9.5 in vagina between treated and untreated mice, the differences in other tissues did not reach statistical significance. It is unclear whether this is due to lack of genuine difference, or to lack of statistical power, or due to the possible antiinflammatory effect of DMSO.
Regardless, the correlation between Trpv1 staining in ectopic endometrium and hotplate latency as well with serum TNFa levels, and between serum TNFa levels and Pkc1 and Pgp9.5 staining in eutopic endometrium suggests that the involvement of TNFa, TRPV1, PKC1 and PGP9.5 in endometriosis-induced nociceptive hypersensitivity (Cunha et al., 1992) . In addition, the reduction in Trpv1, Pkc1 and Pgp9.5 immunoreactivity as a result of TSA treatment, along with improved nociceptive threshold, strongly suggests the potential of HDACIs as therapeutics for endometriosis.
Unresolved issues
Although it has been reported that SHAM rats do not have increased vaginal hyperalgesia as do in rats with induced endometriosis (Berkley et al., 2001) , the mice in our experiment, however, did show decreased thermal latency. Difference in species and the test mode may also contribute to this discrepancy. We did observe signs of adhesion in SHAM mice and adhesion has been documented to be surrounded by sensory nerve fibers (Sulaiman et al., 2000 (Sulaiman et al., , 2001 and is associated with pelvic pain (Hammoud et al., 2004) . The vaginal hypersensitivity as reported by Berkley and her associates (Berkley et al., 2001 (Berkley et al., , 2007 ) is a form of enhanced visceral mechanosensitivity whereas reduced hotplate latency signals are due to increased thermal hypersensitivity.
Summary
In summary, our study provides evidence that treatment with TSA reduces the average lesion size as well as thermal hypersensitivity in experimentally induced endometriosis in mice as compared with those without the TSA treatment. These data, along with mounting evidence that endometriosis is an epigenetic disease, suggest that HDACIs may be promising therapeutics for treating endometriosis.
